Europe Small Molecule Drug Delivery Market Overview and Growth by 2027

Europe small molecule drug delivery market is expected to reach US$ 13,381.71 million by 2027 from US$ 6,835.97 million in 2019. The market is anticipated to grow with a CAGR of 9.0% from 2020 to 2027.

Small molecules drugs are used in targeted drug delivery in which small molecules pass through the cell membrane and acts on the specific cellular organelle or protein. The small molecules drugs are able to enter cells easily because of its low molecular weight. These molecules are better than monoclonal antibodies and other large molecule drugs due to their size, easy convertibility to oral form and cost affectivity. The discovery of novel small molecule entities that are capable of specific interactions represents a significant challenge in the early stages of drug discovery.

Germany Small Molecule Drug Delivery Market Revenue and Forecast to 2027 (US$ Million)

Market Insights

Growing Developments and Start-Ups in Small Molecules Drug Delivery Market

Small molecules offer innovative medications for the four significant indications, such as oncology, diabetes, autoimmune, and respiratory diseases. For instance, combination with large molecules as antibody-drug conjugates (ADC), allowing more precise treatment of cancer. Additionally, small molecule protein kinase inhibitors are becoming increasingly important in cancer therapy. This has led to increasing product approvals of small molecule drugs and growing number of start-up companies, which are the prime factors for the growth of the small molecule drug discovery market.

Hungray based ChemPass founded in 2016, generate molecular structures based on user-defined criteria. It design novel small organic molecules and scaffolds. Additionally, Molomics headquarter in Barcelona, Catalonia, Spain uses artificial intelligence (AI) in drug discovery to design structurally new small molecules for validated biological targets. This allows researchers to collaborate with each other (using what they call "Human Collective Intelligence") and AI to jointly develop safer and more effective therapeutics. Owing to above mentioned factors, the market for small molecule drug delivery is likely to grow in the forecasted period.

Therapeutic Type- Based Market Insights

Based on therapeutic type, the small molecule drug delivery market is further segmented into oncology, central nervous system, cardiovascular, respiratory, orthopedics, immunology, rare diseases, and other therapeutic areas. The oncology segment held the largest share of the market in 2019, however, rare diseases is anticipated to register the highest CAGR in the market during the forecast period.

Europe Small Molecule Drug Delivery Market, by Therapeutic Type– 2019 and 2027

Process/Phase -Based Market Insights

Based on process/phase, the small molecule drug delivery market is segmented into target discovery, target validation, lead generation and refinement, and preclinical development. The lead generation and refinement segment held the largest share of the market in 2019. Moreover, target discovery is estimated to register the highest CAGR during the forecast period.

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Product launches and approvals are commonly adopted strategies by companies to expand their footprint worldwide and meet the growing demand. The players operating in the small molecule drug delivery market adopt the expansion, collaboration, and product launch strategies to enlarge customer base across the world. These strategies allow the players to maintain their brand name globally. For instance, in May 2018, Cloud Pharmaceuticals, Inc., an AI-driven drug design and development company, entered into drug discovery collaboration with GlaxoSmithKline (GSK), wherein Cloud will bedesigning novel small-molecule agents for GSK specified targets through its proprietary AI-driven process to design the molecules.

By Therapeutic Area

• Oncology
• Central Nervous System
• Cardiovascular
• Respiratory
• Orthopedics
• Immunology
• Rare Diseases
• Other Therapeutic Areas

By Process/Phase

• Target Discovery
• Target Validation
• Lead Generation and Refinement
• Preclinical Development

By Country

Europe

• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Company Profiles

• Merck KGaA
• GlaxoSmithKline plc
• AstraZeneca
• Boehringer Ingelheim International GmbH
• Allergan Plc
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc.
• Teva Pharmaceutical Industries Ltd

Report Scope

Europe Small Molecule Drug Delivery Market Regional Insights

The regional trends and factors influencing the Europe Small Molecule Drug Delivery Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Europe Small Molecule Drug Delivery Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Europe Small Molecule Drug Delivery Market Report Scope

Europe Small Molecule Drug Delivery Market Players Density: Understanding Its Impact on Business Dynamics

The Europe Small Molecule Drug Delivery Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Europe Small Molecule Drug Delivery Market are:

1. Merck KGaA
2. GlaxoSmithKline plc
3. AstraZeneca
4. Boehringer Ingelheim International GmbH
5. Allergan Plc

Disclaimer: The companies listed above are not ranked in any particular order.